Sequent Scientific Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Sequent Scientific şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

-0.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.2%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	₹0.500
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

Sep 27

What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You

Sep 05

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

Jan 05

What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Dec 24

Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?

Dec 12

Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly

Nov 22

Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)

Nov 10

The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It

Oct 20

How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?

Oct 05

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SEQUENT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SEQUENT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Sequent Scientific Piyasaya Karşı Temettü Getirisi

SEQUENT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SEQUENT)	0%
Pazarın Alt %25'i (IN)	0.2%
Pazarın En İyi %25'i (IN)	1.1%
Sektör Ortalaması (Pharmaceuticals)	0.7%
Analist tahmini (SEQUENT) (3 yıla kadar)	n/a

Önemli Temettü: SEQUENT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SEQUENT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SEQUENT Indian piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SEQUENT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Sequent Scientific Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024)

Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024

Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director

Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million

Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion.

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You

Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024

Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹0.26 (vs ₹1.40 loss in 1Q 2024)

Sequent Scientific Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings released: ₹1.44 loss per share (vs ₹4.88 loss in FY 2023)

Sequent Scientific Limited to Report Q4, 2024 Results on May 15, 2024

Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)

Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024

Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023)

Sequent Scientific Limited Announces Executive Changes

Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024

Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024

Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023

Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer

Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023

Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023

Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra

Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022)

Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet

Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022)

Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director

Price target decreased to ₹149

High number of new and inexperienced directors

Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022)

Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion.

Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022

Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022

First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022)

Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022

Investor sentiment improved over the past week

Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer

Investor sentiment deteriorated over the past week

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022

Price target decreased to ₹170

High number of new and inexperienced directors

Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022

Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO

Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director

CEO, MD & Executive Director recently sold ₹73m worth of stock

Investor sentiment improved over the past week

CEO, MD & Executive Director recently sold ₹84m worth of stock

CEO, MD & Executive Director recently sold ₹23m worth of stock

CEO, MD & Executive Director recently sold ₹27m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to ₹197

Insider recently sold ₹5.7m worth of stock

Investor sentiment deteriorated over the past week

Insider recently bought ₹1.4m worth of stock

Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021)

Investor sentiment deteriorated over the past week

Insider recently sold ₹17m worth of stock

Insider recently sold ₹17m worth of stock

Full year 2021 earnings released: EPS ₹3.87 (vs ₹2.87 in FY 2020)

Insider recently sold ₹1.3m worth of stock

Third quarter 2021 earnings released: EPS ₹1.54 (vs ₹0.83 in 3Q 2020)

New 90-day high: ₹232

Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?

Sequent Scientific Limited to Report Q3, 2021 Results on Feb 03, 2021

New 90-day high: ₹215

Investor sentiment improved over the past week

How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

New 90-day high: ₹181

What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Chief Financial Officer recently sold ₹7.7m worth of stock